Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma.
CONCLUSION: The observed axitinib concentrations were at least an order of magnitude lower than expected based on the literature and measurements in other patients. The present case report indicates a potential risk of axitinib underdosing in patients on hemodiafiltration with the standard dose; therefore, drug dosage may need to be corrected based on the plasma levels of axitinib.
PMID: 29765173 [PubMed - as supplied by publisher]
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Carcinoma | Clear Cell Carcinoma | Clinical Trials | Czechia Health | Dialysis | Hemodiafiltration | Hemodialysis | Kidney Cancer | Nephrectomy